Sr. Director, U.S. Asset Lead - Oncology (Lung & GU Tumors)

GSK•Philadelphia, PA

14h•Onsite

About The Position

The Sr. Director, U.S. Asset Lead is the primary U.S. commercial representative for the asset across lung and genitourinary (GU) tumors. This leader embeds U.S. market perspective into clinical development, regulatory and access strategy, and launch planning to maximize commercial value from development through lifecycle management. The role partners with global and U.S. functions to ensure development decisions support U.S. commercialization.

Requirements

Bachelor’s degree in business, life sciences, healthcare or related field; advanced degree preferred.
10+ years in biopharma with substantial oncology commercial experience.
Demonstrated experience supporting late-stage clinical development, launch planning, and/or commercialization of oncology assets
Experience collaborating with cross‑functional stakeholders across Commercial, Medical, Regulatory, Market Access, and Forecasting in matrixed environments
Proven success influencing global, matrixed teams.

Nice To Haves

Advanced degree (MBA, PhD, PharmD, MD, or equivalent)
Direct commercial experience in lung cancer and/or genitourinary (GU) tumor indications
Experience serving as an asset lead or primary commercial representative on a global asset team
Hands-on involvement in U.S. launch execution, including positioning, pricing, access strategy, and go‑to‑market planning
Deep familiarity with U.S. payer evidence requirements, value frameworks, and access strategy for oncology therapies

Responsibilities

Act as U.S. commercial lead ensuring U.S. priorities are reflected in global asset decisions.
Define U.S. Target Product Profile, positioning, differentiation and value proposition versus competitors.
Translate U.S. market insights into actionable guidance for global teams.
Provide commercial input on indication prioritization, endpoints, comparator strategy, and trial design.
Identify label-optimizing opportunities and evidence needs to support U.S. access and adoption.
Support U.S. market landscape analyses: epidemiology, treatment pathways, competitive pipelines and emerging modalities.
Partner with Business Insights/Analytics to surface signals that drive strategic shifts.
Collaborate on U.S. revenue forecasting, scenario planning and pricing/market uptake assumptions.
Inform investment, launch sequencing and lifecycle decisions with commercial assessments.
Inform U.S. launch planning: customer segmentation, messaging, access/pricing strategy and go-to-market model.
Support in the cross functional commercialization planning: Sales, Marketing, Market Access and Medical Affairs for coordinated launch execution.
Integrate with Global Asset Team, Medical, Regulatory, Market Access, and Forecasting.
Engage KOLs, advocacy groups and present at major oncology congresses to inform strategy and market shaping.